LOGIN  |  REGISTER
Cue Biopharma

List of Pharma and Biotech Companies Developing Obesity Drugs

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 796.28
28.52 3.71
3.23M
899.32M
US$ 716.110B
US$ 88.75
3.75 4.41
18.64M
3.37B
US$ 299.090B
US$ 99.37
1.32 1.35
7.93M
2.53B
US$ 251.410B
US$ 114.31
1.89 1.68
3.45M
1.73B
US$ 197.760B
US$ 34.91
0.39 1.13
376,191
5.52B
US$ 192.700B
US$ 26.71
0.35 1.33
33.60M
5.67B
US$ 151.450B
US$ 264.00
0.62 0.24
1.63M
537.53M
US$ 141.910B
US$ 22.21
0.12 0.54
7.39M
1.13B
US$ 25.100B
US$ 369.76
1.60 0.43
278,563
59.38M
US$ 21.960B
US$ 227.84
-0.77 -0.34
499,249
83.64M
US$ 19.060B
US$ 43.96
-0.82 -1.83
758,304
93.62M
US$ 4.120B
US$ 36.15
-0.11 -0.30
802,827
101.12M
US$ 3.660B
US$ 56.04
-0.08 -0.14
982,639
61.46M
US$ 3.440B
US$ 19.75
0.30 1.54
1.32M
124.43M
US$ 2.460B
US$ 13.12
-0.39 -2.89
667,270
152.52M
US$ 2.000B
C$ 7.21
0.11 1.55
1.37M
248.96M
C$ 1.800B
US$ 28.58
0.68 2.44
822,806
57.26M
US$ 1.640B
US$ 9.12
-0.32 -3.39
3.48M
172.17M
US$ 1.570B
US$ 17.12
0.09 0.53
876,205
40.51M
US$ 693.530M
US$ 7.76
-0.49 -5.94
4.03M
71.12M
US$ 551.890M
US$ 0.83
0.12 16.13
10.31M
361.49M
US$ 300.040M
US$ 4.99
-0.05 -0.99
583,897
43.31M
US$ 216.120M
US$ 5.94
-0.20 -3.26
1.58M
35.85M
US$ 212.950M
US$ 2.35
0.11 4.91
1.49M
70.71M
US$ 166.170M
US$ 4.97
0.02 0.40
340,147
30.67M
US$ 152.430M
US$ 0.65
-0.0021 -0.32
1.41M
146.38M
US$ 94.710M
US$ 1.90
0.11 6.15
447,021
48.10M
US$ 91.390M
US$ 2.63
-0.07 -2.59
839,588
30.34M
US$ 79.790M
US$ 0.46
0.0095 2.12
4.84M
166.19M
US$ 75.950M
US$ 0.40
-0.21 -33.94
179.68M
186.89M
US$ 75.500M
US$ 2.00
-0.10 -4.76
477,342
36.83M
US$ 73.660M
US$ 0.68
-0.09 -12.00
1.39M
103.82M
US$ 70.810M
US$ 1.18
0.00 0.00
122,515
59.23M
US$ 69.890M
US$ 3.21
-0.06 -1.83
118,397
19.01M
US$ 61.020M
US$ 2.20
-0.03 -1.35
55,887
17.45M
US$ 38.390M
C$ 0.54
-0.03 -5.26
11,500
47.65M
C$ 25.730M
US$ 4.80
-0.07 -1.44
60,053
5.35M
US$ 25.680M
US$ 0.70
-0.10 -12.75
212,985
34.10M
US$ 23.800M
US$ 0.35
-0.001 -0.29
403,062
64.80M
US$ 22.490M
US$ 2.36
-0.12 -4.84
51,873
9.15M
US$ 21.590M
US$ 2.36
0.00 0.00
0
8.49M
US$ 20.040M
US$ 0.95
-0.02 -1.85
3.09M
19.55M
US$ 18.570M
US$ 2.11
0.02 0.96
171,734
8.71M
US$ 18.380M
US$ 0.60
0.02 2.93
167,277
23.26M
US$ 13.960M
C$ 0.03
0.00 0.00
60,000
541.70M
C$ 13.540M
US$ 4.46
-0.01 -0.22
83,476
2.86M
US$ 12.760M
US$ 1.51
-0.04 -2.58
15,841
6.92M
US$ 10.450M
US$ 1.46
-0.02 -1.35
85,540
6.10M
US$ 8.910M
US$ 6.32
-0.18 -2.77
15,743
1.28M
US$ 8.090M
US$ 2.48
0.00 0.00
44,872
2.49M
US$ 6.180M
US$ 0.82
0.008 0.99
89,632
6.90M
US$ 5.640M
US$ 1.22
0.02 1.67
34,095
4.38M
US$ 5.340M
US$ 1.11
-0.15 -11.90
14.33M
4.31M
US$ 4.780M
US$ 0.50
0.01 2.04
17,472
6.96M
US$ 3.480M
US$ 1.17
0.03 2.63
74,678
2.34M
US$ 2.740M
US$ 0.23
0.02 9.24
2.23M
10.36M
US$ 2.410M
C$ 0.005
0.00 0.00
6,651
173.26M
C$ 866K
US$ 1.20
0.00 0.00
44,455
-
US$ -

Latest News From Companies Developing Obesity Drugs


Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity

WVE-007 is a novel approach for treating obesity and is designed to silence INHBE to achieve healthy, sustainable weight loss through fat burning, muscle maintenance and the potential for once or twice-annual administration WVE-007 is Wave’s first siRNA program to enter clinical development and uses best-in-class oligonucleotide chemistry and GalNAc delivery Wave expects to initiate the first-in-human study of WVE-007 in 1Q 2025 CAMBRIDGE, Mass., Dec. 23, 2024... Read more


Novo Nordisk: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial

Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual components cagrilintide 2.4 mg, semaglutide 2.4 mg and placebo, all administered once-weekly. The trial included 3,417 randomised... Read more


Eli Lilly: FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity

 Averaging up to 20% of weight loss, adults taking Zepbound had at least 25 fewer breathing interruptions each hour as they slept Up to 50% of adults taking Zepbound no longer had symptoms associated with OSA after one year INDIANAPOLIS, Dec. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moder... Read more


TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs

Fully funded study to evaluate Wegovy and Ozempic patients at risk for increased inflammation associated with sarcopenic muscle deterioration Collaboration partner to use AI and machine learning to identify targeted patient pool Potential entry into high growth GLP-1 market valued at nearly $50 billion in 2024 and projected to surpass $100 billion by 2029 BALTIMORE / Dec 19, 2024 / Business Wire / TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNFA” or the “Company”),... Read more


Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

NPM-115 clinical program utilizes a miniature, GLP-1 (exenatide) implant designed to provide comparable efficacy to semaglutide, with twice-yearly administration Study represents the first clinical application of NanoPortal™, the Company’s proprietary drug implant platform technology ALAMEDA, Calif. / Dec 19, 2024 / Business Wire / Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing novel, ultra... Read more


Bio-Path Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity

HOUSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today reported that results from preclinical studies of BP1001-A for obesity demonstrated enhanced insulin sensitivity, confirming BP1001-A as a potential treatment for obesity and related metabolic diseases in Type 2 diabetes... Read more


Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist

RAHWAY, N.J. / Dec 18, 2024 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical company, today announced that they have entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist. “We continue to leverage science-driven business development to augment and complement our robust pipeline,” said Dr. Dean Y.... Read more


Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans ACCG-2671 is the most advanced oral small molecule amylin-based drug candidate, with Phase 1 study initiation expected by year end 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR),... Read more


Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results...

The ongoing obesity Phase 2 trial is a randomized, double-blind, placebo-controlled, dose finding, clinical trial to evaluate the safety and efficacy of KDS2010 in approximately 75 overweight or obese patients currently enrolling in South Korea with a cohort in U.S. to be added in 2025. KDS2010 has shown promising preclinical results with a novel mechanism of blocking MAO-B-dependent aberrant GABA (gamma-aminobutyric acid) production in reactive astrocytes and eliminates... Read more


Bio-Path Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients

Extensive Scientific Evidence Supporting Growth Factor Receptor Bound Protein-2 (Grb2) as Fundamental Link in Insulin Resistance Reallocates Resources to Metabolic Program and Discontinues Enrollment in Phase 1 Study of BP1002 to Treat Relapsed/Refractory Lymphoma and Relapsed/Refractory Chronic Lymphocytic Leukemia Due to Enrollment Challenges in Niche Patient Populations HOUSTON, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology... Read more


BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity

Decision follows observations of liver transaminitis without clinically significant symptoms in some subjects on azelaprag Company will evaluate data from patients enrolled to date and share updated plans for azelaprag in Q1 2025 In parallel to evaluating azelaprag, Company will continue to advance earlier platform-derived programs, including IND submission for CNS penetrant NLRP3 inhibitor anticipated in the second half of 2025 RICHMOND, Calif., Dec. 06, 2024 (GLOBE... Read more


Eli Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%

Participants using Zepbound lost 50.3 lbs (22.8 kg) and participants on Wegovy lost 33.1 lbs (15.0 kg) SURMOUNT-5 compared Zepbound, a dual GIP and GLP-1 receptor agonist, to Wegovy, a mono GLP-1 receptor agonist in adults living with obesity without diabetes INDIANAPOLIS, Dec. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. Zepbound® (tirzepatide)... Read more


Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

In preclinical studies, investigational ARO-ALK7 silenced Activin receptor-like kinase 7 (ALK7) expression in adipose tissue, which led to reduced body weight and fat mass with preservation of lean muscle PASADENA, Calif. / Dec 03, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-ALK7, the company’s second investigational RNA interference... Read more


Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl...

BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the United Kingdom’s Medicines & Healthcare products Regulatory Agency (MHRA) has expanded the marketing authorization for IMCIVREE® (setmelanotide) to include the treatment of obesity and control of hunger associated... Read more


Amgen Announces Robust Weight Loss with Maritide in People Living with Obesity or Overweight at 52 Weeks in Phase 2 Study

MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in People Living With Obesity or Overweight MariTide is the First Obesity Treatment With Monthly or Less Frequent Dosing to Demonstrate Safe and Effective Weight Loss in a Phase 2 Study In People With Type 2 Diabetes Living With Obesity or Overweight MariTide Demonstrated up to ~17% Average Weight Loss Without a Weight Loss Plateau and Lowered Average HbA1c by up to 2.2 Percentage... Read more


Allurion Technologies Launches in the US with its First AI-Native Compounded GLP-1 Program

AllurionMeds is designed to address a critical demand from patients: The Weight Must Stay Off Features Coach Iris, a first-of-its-kind conversational AI behavioral agent for weight loss and maintenance, trained using real-world experience in over 150,000 patients Compounded GLP-1 program designed to provide long-term behavioral change while addressing weight re-gain and other negative side effects for patients Expands Allurion’s presence to all 50 states, helping to... Read more


Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity

In the RESILIENT SMA study, taldefgrobep alpha showed clinically meaningful improvements in motor function at all timepoints on the Motor Function Measurement-32 scale (MFM-32), but the treatment arm did not statistically separate on the primary outcome at Week 48 compared to the placebo+standard of care (SOC) group. Efficacy signals were observed in clinically relevant and biomarker-defined subgroups including those related to age, ambulatory status, background... Read more


Eli Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity

In a first-of-its-kind study, tirzepatide also alleviated heart failure symptoms and physical limitations Patients on tirzepatide experienced improved exercise capacity, greater weight loss and reduced systemic inflammation Lilly has initiated submissions for tirzepatide for the treatment of HFpEF and obesity to global regulatory agencies INDIANAPOLIS, Nov. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the... Read more


Lexaria Bioscience Signs Contract For New DehydraTECH GLP-1 Biodistribution Study

World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / November 14, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has engaged a contract research organization to perform the world's first-ever fluorescently tagged DehydraTECH-semaglutide ("FTS") rodent biodistribution study (the "Study"). Distribution... Read more


Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor

SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that it has achieved more than 50% of targeted patient enrollment for its CBeyond™ Phase 2 clinical trial assessing nimacimab, a differentiated CB1 inhibitor, in patients with overweight or obesity. Skye expects to report interim data for the... Read more


Eli Lilly: Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks

SURMOUNT-1 results show a 94% reduction in risk of progression to type 2 diabetes across all pooled doses of tirzepatide compared to placebo over three years Results suggest one new case of diabetes could be prevented for every nine patients treated with tirzepatide Participants treated with tirzepatide had an average weight reduction of 22.9% (15 mg dose) INDIANAPOLIS, Nov. 13, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today detailed results... Read more


Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Phase 2b ACCESS study designed to evaluate multiple doses up to 120 mg of GSBR-1290 over 36 weeks Comprehensive development program also includes Phase 2 ACCESS II study to evaluate even higher doses of GSBR-1290 over 36 weeks; first patient expected to be dosed by end of 2024 Topline data from both ACCESS and ACCESS II studies expected in the fourth quarter of 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Nov.... Read more


Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss

DehydraTECH clinical test article manufacturing has been completed KELOWNA, BC / ACCESSWIRE / November 13, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has received lead clinical site human research ethics committee ("HREC") approval that was required before dosing can begin in the Company's Phase 1b, 12-week chronic study GLP-1-H24-4, (the "Study"). The Company is also... Read more


Lexaria Bioscience Updates Fast-Moving GLP-1 'Arm's Race' Developments

DehydraTECH™ for GLP-1 being optimized for global pharmaceutical use KELOWNA, BC / ACCESSWIRE / November 7, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms provides the following glucagon-like peptide-1 ("GLP-1") industry update. It is no surprise that Novo Nordisk's ("Novo") blockbuster drug, semaglutide, which is sold under the brand names Ozempic®, Wegovy®, and Rybelsus®,... Read more


Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity

Company and Agency aligned on key efficacy and safety measures to be studied in Phase 3 program Pivotal Phase 3 trials designed to leverage the differentiated attributes of pemvidutide and potential benefits of balanced GLP-1/glucagon dual agonism GAITHERSBURG, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the successful completion of its End-of-Phase 2 Meeting with the U.S. Food and... Read more


Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek®...

13-week follow-up represents the longest data to-date demonstrating durable efficacy of RJVA-001 on weight and blood sugar in the diet-induced obesity (DIO) mouse model Company plans to use durable efficacy results as part of its FIH data package for RJVA-001 Fractyl also announces the nomination of RJVA-002, a GIP/GLP-1 dual agonist, as its first pancreatic gene therapy candidate for obesity BURLINGTON, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Fractyl Health,... Read more


Lexicon Pharmaceuticals to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss

Investigational New Drug (IND) application planned in 2025 for LX9851, a first-in-class, potent, selective, orally bioavailable molecule, as an anti-obesity agent Data from Lexicon’s Obesity Week presentations summarize the preclinical efficacy and mechanism of action of LX9851 THE WOODLANDS, Texas, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it will present data from two studies related to LX9851,... Read more



Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced positive results demonstrating the anti-inflammatory potential of our anti-CD3 antibody (foralumab) in combination with semaglutide, a GLP-1 agonist marketed... Read more


Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study

DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing weight loss groups Accelerated rates of weight loss were experienced during the final 4 weeks of the study in all DehydraTECH groups KELOWNA, BC / ACCESSWIRE / October 22, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received partial 12-week (final) body... Read more


WELL Health Technologies' Subsidiary Wisp Launches Comprehensive Weight Care Vertical Inclusive of GLP-1 Medications to Support Women Struggling with Hormonal Imbalances

Wisp debuts its first-ever exclusive over-the-counter weight-loss supplement, designed to promote women's metabolic health. Wisp introduces personalized, online consultations with access to four weight care solutions, including GLP-1 medications, to support women struggling with hormonal conditions such as perimenopause, menopause, Polycystic Ovary Syndrome (PCOS), and endometriosis. With over 1.2 million patients, Wisp Now Also Bolsters its Menopause Solutions, Empowering... Read more


iBio and AstralBio Provide Update on Myostatin Program for Obesity

SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today provided an update on the myostatin program for cardiometabolic disease and obesity in collaboration with AstralBio. iBio’s technology stack enabled the Company to rapidly advance the joint myostatin program from inception to in vitro proof-of-concept in human muscle cells. Following early discovery, the companies have identified a... Read more


Allurion Technologies Announces Publication of New Data Demonstrating Muscle Mass Preservation in Patients Experiencing 15% Weight Loss

In a study of 167 patients, average weight reduction was 15.7% at four months, 17.1% at six months, and 14.7% at one year Body fat percentage decreased at six months with no change in muscle mass NATICK, Mass. / Oct 09, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study in the journal Clinical Obesity on the impact of the Allurion Program on weight reduction and body com... Read more


Lexaria Bioscience Updates Current GLP-1 Market

KELOWNA, BC / ACCESSWIRE / October 8, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery technology, provides an update on recent glucagon-like peptide-1 ("GLP-1") receptor agonist market sector advancements. In 2020 the total market size for GLP-1 drugs was less than $4 billion . That same year, Novo Nordisk® paid $1.8 billion to purchase Emisphere's® SNAC drug delivery technology which... Read more


Bio-Path Initiates Development of Therapeutic Program for Treatment of Obesity

HOUSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the initiation of a therapeutic program to develop BP1001-A for the treatment of obesity and related metabolic diseases. This program marks the first application of DNAbilize technology for development of a... Read more


Mangoceuticals Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions

Dallas, Texas, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and wellness products via a secure telemedicine platform, announces the release of its latest innovation, “TRIM,” a compounded, oral dissolvable Tirzepatide tablet. Available for purchase at $399 per month, this new product offers patients an advanced and convenient alternative... Read more


Allurion Technologies Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight Loss

Systematic review of 11 studies involving 2,107 patients reports average weight reduction of 12.5% with significant improvements in metabolic health NATICK, Mass. / Oct 01, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a systematic review and meta-analysis evaluating the effectiveness and safety of the Allurion Program. The analysis reviewed studies conducted between 2016 and... Read more


Mangoceuticals Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment

MangoRx aims to capitalize on growing demand for GLP-1 treatments to drive revenue growth and expand market share in the weight loss category Dallas, Texas, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and wellness products via a secure telemedicine platform, proudly announces that its highly anticipated oral Semaglutide weight loss... Read more



NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Data Revealed Favorable Safety, Tolerability and Dose-Linear Pharmacokinetics (PK) Top-Line Data Readout from the MAD Part 2 Expected in the First Quarter of 2025 Planned Phase 1 Part 3 Will Evaluate Early Proof of Concept CAMBRIDGE, Mass., Sept. 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive top-line safety, tolerability,... Read more


Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3

First-ever DehydraTECH-processed tirzepatide from Zepbound® to be tested in a swallowed oral format KELOWNA, BC / ACCESSWIRE / September 27, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that approval has been received from an independent review board, for human pilot study #3 (the "Study"), investigating a DehydraTECH-processed version of the dual action... Read more


Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders

JERUSALEM and MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (Entera), a leader in the development of orally delivered peptides, and OPKO Health, Inc. (NASDAQ: OPK) (OPKO) announced today topline pharmacokinetic/pharmacodynamic (PK/PD) results from their ongoing collaborative research combining a proprietary long-acting oxyntomodulin (OXM) analog developed by OPKO and Entera’s proprietary N-Tab™ technology. The program is focused on developing... Read more


Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

In preclinical studies ARO-INHBE reduced body weight and fat mass with a novel mechanism of action that may preserve lean muscle mass compared to currently approved obesity therapies PASADENA, Calif. / Sep 23, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA interference (RNAi) therapeutic being developed... Read more


Novo Nordisk: Monlunabant phase 2a trial in obesity successfully completed

Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc. announced in August 2023 [Link]. The trial investigated the efficacy and safety of a once-daily 10 mg, 20 mg and 50 mg dose of monlunabant compared to placebo on body weight... Read more


Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity

Topline results expected in 2Q 2025 CAMBRIDGE, Mass. / Sep 10, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced it has completed enrollment in the Phase 2 EMBRAZE trial designed to show proof-of-concept of apitegromab, an inve... Read more


Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes

Lean Loss Ratio of only 21.9%, representing class-leading preservation of lean mass Maintenance of lean mass preservation in individuals over the age of 60, a population at risk for frailty-related falls and fractures Visceral adipose tissue (VAT), a risk factor for cardiovascular disease, reduced by 25.6% at Week 48 GAITHERSBURG, Md., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data... Read more



Allurion Technologies Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity

In a study of 91 adolescents, average weight loss was 13.1% at four months with no serious adverse events NATICK, Mass. / Sep 05, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study on the safety and effectiveness of the Allurion Program in adolescents. In the study, 91 adolescents between 15 and 17 years-old with average body mass index (BMI) of 35.6 received the Allurion... Read more


23andMe: Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program

SUNNYVALE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., (Nasdaq: ME), and a leading telemedicine provider, is now offering Ozempic®, Wegovy® and compounded semaglutide through a weight loss program on its telehealth platform, providing consumers with access to affordable weight management care through a convenient subscription-based model. If prescribed, Lemonaid Health patients will now have access to once-weekly... Read more


First Results from Lexaria's Second GLP-1 Human Pilot Study

Trend toward higher overall absorption under fed conditions evidenced with DehydraTECH®-processed Rybelsus® KELOWNA, BC / ACCESSWIRE / August 27, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that the first results from human pilot study #2, GLP-1-H24-2 (the "Study"), have been received. Lexaria's DehydraTECH®-processed Rybelsus® evidenced a trend toward higher... Read more

COPYRIGHT ©2023 HEALTH STOCKS HUB